Moss, 12 March 2026
Gentian Diagnostics ASA (the "Company") has completed the offer of new shares to
employees in the Company and its subsidiaries under the Gentian Employee Share
Purchase Program (the "Employee Share Purchase Program"). The application period
expired on 11 March 2026 at 16:00 CET. Under the program, each participating
employee could subscribe for shares for a maximum total subscription amount of
NOK 100,000.
The offer price for the shares in the Employee Share Purchase Program has been
set to NOK 32.58 per share (the "Offer Price"). The Offer Price is based on the
volume-weighted average share price for the Company's shares on the Oslo Stock
Exchange during the ten trading days from 12 February 2026 to and including 25
February 2026, less a discount of 20%. Shares acquired under the Employee Share
Purchase Program will be subject to a lock-up period of one year.
Based on the applications received, the board of directors has allocated a total
of 36,274 new shares to participants in the Employee Share Purchase Program (the
"Program Shares").
The board of directors has, based on the authorisation granted by the annual
general meeting held on 6 May 2025, resolved to increase the Company's share
capital by NOK 3627,4 through the issuance of 36,274 new shares, each with a
nominal value of NOK 0,10, at a subscription price equal to the Offer Price.
Following registration of the share capital increase with the Norwegian Register
of Business Enterprises (Nw.: Foretaksregisteret), the Company's share capital
will be NOK 1,545,862.4, divided into 15,458,624 shares, each with a nominal
value of NOK 0,10.
For further information, please contact:
IR contact:
Njaal Kind, CFO
njaal.kind@gentian.no
+47 919 06 525 (mobile)
This information is subject to the disclosure requirements pursuant to Section
5-12 of the Norwegian Securities Trading Act.
About Gentian Diagnostics
Gentian Diagnostics (OSE: GENT), develops and manufactures high-quality, in
vitro diagnostic reagents. Our mission is to innovate diagnostic efficiency for
better treatment decisions. Gentian's expertise and focus lie within
immunoassays, specifically for infections, inflammation, kidney disease and
heart failure. By converting existing and clinically relevant biomarkers to the
most efficient, high-throughput analysers, the company contributes to saving
costs and protecting life. Gentian Diagnostics is headquartered in Moss, Norway,
serving the global human and veterinary diagnostics markets through sales and
representative offices in Sweden, USA, and China. For more information, please
visit www.gentian.com.